Basilea Pharmaceutica

The Basilea Pharmaceutica AG is a biopharmaceutical company with headquarters in Basel, Switzerland. It was spun off in 2000 from F. Hoffmann -La Roche and is listed as a separate company on the Swiss Stock Exchange since March 2004. Its market capitalization stood at the end of May 2008 nearly 1.6 billion Swiss francs.

Field of activity

The research and development operations are focused on drugs to treat resistant bacterial infections, and fungal diseases and dermatology drugs.

Basilea's products are targeted to satisfy high medical and patient needs. The product portfolio of the company includes two products in the pre-registration and one in the final stages of development. These are to:

Alitretinoin, an oral retinoid for the treatment of chronic hand eczema unresponsive to topical steroids.

Ceftobiprole, a cephalosporin antibiotic with activity against MRSA and a spectrum of activity that is developed in collaboration with Johnson & Johnson.

Isavuconazole, a novel antifungal spectrum of activity for the treatment of severe invasive fungal infections.

The company is currently building its sales and marketing organization in order, subject to approval of alitretinoin, ceftobiprole alone and to market to co-promote.

107353
de